AKT and MAPK are the two cell signaling pathways governing viability of colorectal cancer cell lines with different receptor expression patterns.

<p>Differences in cell viability in LoVo (A, B) and SW948 (C, D) cells following treatment with different agonists or inhibitors, as indicated. The data are presented as mean±SD, and **P<0.01 by unpaired Student’s t test.</p

Activation of MAPK or AKT signaling in colorectal cancer cells with different molecular patterns of expression.

<p>(A, B) Detection of AKT and MAPK signaling in SW948 and LoVo cells by western-blot, with the treatment indicated in the figure. (C, D) Detection of AKT and MAPK signaling by western-blot in LoVo and SW948 cells with HGF or HRG1-β1 treatment, with or without different agonists or antagonists, as indicated.</p

Expression of ErbB3, ErbB2 and c-MET in human colorectal cancer.

<p>(A, B, C) Expression of ErbB3, ErbB2 and c-MET in human colorectal cancer. Specimens of 105 paraffin-embedded colorectal cancer tissues were analyzed by IHC for ErbB3, ErbB2 and c-MET, and representative figures show strong and weak/negative staining for each marker with respective normal control samples. Average integrated optical density (IOD) was obtained by analyzing five fields for each slide, evaluated by Image-Pro Plus software (version 5.0) for IHC staining of ErbB3, ErbB2 and c-MET. The data are presented as mean ± SD, and *P<0.05, **P<0.01 by Mann-Whitney U test.</p

Proliferation of colorectal cancer cells is mediated by both ErbB3/ErbB2 and ErbB3/c-MET signaling Pathways.

<p>(A) Detection of ErbB3, ErbB2 and c-MET in the human colorectal cancer cell lines LoVo, sw948 and sw480 by western-blot. (B, C, D) Cell viability measured by MTS assay in the colorectal cancer cell lines LoVo, sw948 and sw480 treated as indicated in the figure. The data are presented as mean ± SD, and *P<0.05, **P<0.01 by unpaired Student’s t test.</p

Heterogeneous expression of ErbB3, ErbB2 and c-MET in human colorectal cancer.

<p>(A) Ratio of strong/moderate/weak/negative staining of ErbB3, ErbB2 and c-MET in human colorectal cancer. (B) Detection of ErbB3, ErbB2 and c-MET in protein extracted from tissue samples of 4 cases of colorectal cancer. (C) Venn diagram showing co-expression of ErbB3, ErbB2 and c-MET.</p